1-20 of 30
Matthew J. Ellis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)

Open Access
Vera J. Suman, Lili Du, Tanya Hoskin, Meenakshi Anurag, Cynthia Ma, Isabelle Bedrosian, Kelly K. Hunt, Matthew J. Ellis, W. Fraser Symmans
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3287–3295.
https://doi.org/10.1158/1078-0432.CCR-22-0068
Published: 02 August 2022
View articletitled, Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
Open the PDF for Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031) in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Available to Purchase
Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View articletitled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer

Free
Xian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, Xixi Cao, Lanfang Qin, Jin-Ah Kim, Ying Tan, Suet Kee Loo, Yiheng Hu, Ling Lin, Sanghoon Lee, Martin J. Shea, Tamika Mitchell, Shunqiang Li, Matthew J. Ellis, Susan G. Hilsenbeck, Rachel Schiff, Xiao-Song Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2648–2662.
https://doi.org/10.1158/1078-0432.CCR-20-2961
Published: 01 May 2021
View articletitled, Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
Open the PDF for Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α

Free
James N. Ingle, Junmei Cairns, Vera J. Suman, Lois E. Shepherd, Peter A. Fasching, Tanya L. Hoskin, Ravinder J. Singh, Zeruesenay Desta, Krishna R. Kalari, Matthew J. Ellis, Paul E. Goss, Bingshu E. Chen, Bernhard Volz, Poulami Barman, Erin E. Carlson, Tufia Haddad, Matthew P. Goetz, Barbara Goodnature, Matthew E. Cuellar, Michael A. Walters, Cristina Correia, Scott H. Kaufmann, Richard M. Weinshilboum, Liewei Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (12): 2986–2996.
https://doi.org/10.1158/1078-0432.CCR-19-3091
Published: 15 June 2020
View articletitled, Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
Open the PDF for Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α in another window
Includes: Supplementary data
Journal Articles

CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?

Available to Purchase
Meenakshi Anurag, Svasti Haricharan, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 3–5.
https://doi.org/10.1158/1078-0432.CCR-19-3119
Published: 03 January 2020
View articletitled, CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?
Open the PDF for CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? in another window
Journal Articles

Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers

Free
Meenakshi Anurag, Nindo Punturi, Jeremy Hoog, Matthew N. Bainbridge, Matthew J. Ellis, Svasti Haricharan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4887–4899.
https://doi.org/10.1158/1078-0432.CCR-17-3702
Published: 01 October 2018
View articletitled, Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers
Open the PDF for Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers in another window
Includes: Supplementary data
Journal Articles

Abstract IA23: Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials

Free
Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1_Supplement): IA23.
https://doi.org/10.1158/1557-3265.TCM17-IA23
Published: 02 January 2018
View articletitled, Abstract IA23: Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials
Journal Articles

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer

Free
Iman Doostan, Cansu Karakas, Mehrnoosh Kohansal, Kwang-Hui Low, Matthew J. Ellis, John A. Olson, Jr., Vera J. Suman, Kelly K. Hunt, Stacy L. Moulder, Khandan Keyomarsi
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7288–7300.
https://doi.org/10.1158/1078-0432.CCR-17-1544
Published: 30 November 2017
View articletitled, Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Open the PDF for Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Free
Cynthia X. Ma, Vera Suman, Matthew P. Goetz, Donald Northfelt, Mark E. Burkard, Foluso Ademuyiwa, Michael Naughton, Julie Margenthaler, Rebecca Aft, Richard Gray, Amye Tevaarwerk, Lee Wilke, Tufia Haddad, Timothy Moynihan, Charles Loprinzi, Tina Hieken, Erica K. Barnell, Zachary L. Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B. Wisinski, Elaine Mardis, Ian S. Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L. Griffith, Malachi Griffith, Laurence Doyle, Charles Erlichman, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 6823–6832.
https://doi.org/10.1158/1078-0432.CCR-17-1260
Published: 14 November 2017
View articletitled, A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Open the PDF for A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Free
Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Karen S. Anderson, Julie Margenthaler, Rebecca Aft, Timothy Hobday, Timothy Moynihan, William Gillanders, Amy Cyr, Timothy J. Eberlein, Tina Hieken, Helen Krontiras, Zhanfang Guo, Michelle V. Lee, Nicholas C. Spies, Zachary L. Skidmore, Obi L. Griffith, Malachi Griffith, Shana Thomas, Caroline Bumb, Kiran Vij, Cynthia Huang Bartlett, Maria Koehler, Hussam Al-Kateb, Souzan Sanati, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4055–4065.
https://doi.org/10.1158/1078-0432.CCR-16-3206
Published: 01 August 2017
View articletitled, NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Open the PDF for NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract IA01: The proteogenomics of breast cancer patient-derived xenografts

Free
Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA01.
https://doi.org/10.1158/1557-3265.PDX16-IA01
Published: 15 August 2016
View articletitled, Abstract IA01: The proteogenomics of breast cancer patient-derived xenografts
Journal Articles

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Free
Cynthia X. Ma, Cesar Sanchez, Feng Gao, Robert Crowder, Michael Naughton, Timothy Pluard, Allison Creekmore, Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Austin Doyle, Charles Erlichman, Matthew J. Ellis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2650–2658.
https://doi.org/10.1158/1078-0432.CCR-15-2160
Published: 31 May 2016
View articletitled, A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Free
Cynthia X. Ma, Jingqin Luo, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine Mardis, Craig Lockhart, Matthew J. Ellis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (7): 1583–1591.
https://doi.org/10.1158/1078-0432.CCR-15-1745
Published: 31 March 2016
View articletitled, A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer

Free
Suzanne E. Wardell, Matthew J. Ellis, Holly M. Alley, Koleen Eisele, Todd VanArsdale, Stephen G. Dann, Kim T. Arndt, Tina Primeau, Elizabeth Griffin, Jieya Shao, Robert Crowder, Jin-Ping Lai, John D. Norris, Donald P. McDonnell, Shunqiang Li
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5121–5130.
https://doi.org/10.1158/1078-0432.CCR-15-0360
Published: 12 November 2015
View articletitled, Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Open the PDF for Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract IA03: Mutations, drugs, and breast cancer: How are we going to figure it out?

Free
Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): IA03.
https://doi.org/10.1158/1557-3265.PMS14-IA03
Published: 13 February 2015
View articletitled, Abstract IA03: Mutations, drugs, and breast cancer: How are we going to figure it out?
Journal Articles

Incorporating Genomics into Breast Cancer Clinical Trials and Care

Free
Adel Tabchy, Cynthia X. Ma, Ron Bose, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6371–6379.
https://doi.org/10.1158/1078-0432.CCR-13-0837
Published: 01 December 2013
View articletitled, Incorporating Genomics into Breast Cancer Clinical Trials and Care
Open the PDF for Incorporating Genomics into Breast Cancer Clinical Trials and Care in another window
Journal Articles

Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data

Free
Theodore C. Goldstein, Evan O. Paull, Matthew J. Ellis, Joshua M. Stuart
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3114–3120.
https://doi.org/10.1158/1078-0432.CCR-12-2093
Published: 13 June 2013
View articletitled, Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data
Open the PDF for Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data in another window
Journal Articles

Abstract IA3: PI3K inhibitors in ER+ breast cancer: Next steps

Free
Matthew J. Ellis, Robert Crowder, Cynthia X. Ma
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): IA3.
https://doi.org/10.1158/1078-0432.MECHRES-IA3
Published: 04 March 2013
View articletitled, Abstract IA3: PI3K inhibitors in ER+ breast cancer: Next steps
Open the PDF for Abstract IA3: PI3K inhibitors in ER+ breast cancer: Next steps in another window
Journal Articles

A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

Free
Stephen K. Chia, Vivien H. Bramwell, Dongsheng Tu, Lois E. Shepherd, Shan Jiang, Tammi Vickery, Elaine Mardis, Samuel Leung, Karen Ung, Kathleen I. Pritchard, Joel S. Parker, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4465–4472.
https://doi.org/10.1158/1078-0432.CCR-12-0286
Published: 14 August 2012
View articletitled, A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Open the PDF for A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen in another window
Includes: Supplementary data
Journal Articles

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Free
Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen K. Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri Davies, Inge J. Stijleman, Carole Davis, Mark T.W. Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2402–2412.
https://doi.org/10.1158/1078-0432.CCR-11-2956
Published: 16 April 2012
View articletitled, Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Open the PDF for Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial in another window
Includes: Supplementary data